<< Вернуться к списку статей журнала

Том 2 №4 2000 год - Нефрология и диализ

Факторы риска кардиоваскулярных заболеваний у больных с хронической почечной недостаточностью

Волгина Г.В. Перепеченых Ю.В. Бикбов Б.Т. Ушакова А.И. Китаева Ю.В. Грябина Н.А. Томилина Н.А.

Аннотация: Кардиоваскулярные заболевания (КВЗ) являются ведущей причиной заболеваемости и летальности больных с хронической почечной недостаточностью (ХПН) в Европе, США и развивающихся странах, составляя около 50-60% всех случаев смерти у диализных больных, что в 20-30 раз превышает летальность в общей популяции [14, 15, 21, 25, 38, 76, 80, 85, 96, 97, 101]. Изучение причин развития КВЗ, их профилактики и лечения у больных с ХПН являются актуальной задачей современной нефрологии.

Для цитирования: Волгина Г.В., Перепеченых Ю.В., Бикбов Б.Т., Ушакова А.И., Китаева Ю.В., Грябина Н.А., Томилина Н.А. Факторы риска кардиоваскулярных заболеваний у больных с хронической почечной недостаточностью. Нефрология и диализ. 2000. 2(4):252-259. doi:

Весь текст

Ключевые слова: ХПН, кардиоваскулярные заболевания, факторы риска, додиализная стадия, лечение ГД и ПД

Список литературы:

1. Кобалова Ж.Д., Терещенко С.Н., Калинкин А.Л. Суточное мониторирование артериального давления: методические аспекты и клиническое значение. - М., 1997. - 32 с.
2. Оганов Р.Г. Первичная профилактика ИБС. - М.: Медицина, 1998. - 158 с.
3. Amann K., Ritz E., Wiest G., Klaus G., Mall G. A role of parathyroid hormone for activation of cardiac fibroblast in uremia. J. Amer. Soc. Nephrol. 1994; 4(10): 1814-1819.
4. Аmann K., Rits E. Cardiac structure and function in renal disease. Curr. Opin. Nephrol. Hypertens. 1996; 5: 102-106.
5. Amann K., Rits E. Cardiac disease in chronic uremia: pathophysiology.Adv. Ren. Replace. Ther. 1997; 4: 212-224.
6. Amann K., Schwarz U., Torning J. et al. Some cardiac abnormalities in renal failure. In: Grunfeld J.P., Bach J.F., Kreis H. (eds). Actualite nephrologiques, Jean Hamburger. Hospital Nekcer 1997. Medicine-Sciences Flammarion, Paris, 1997; 1-15.
7. Anderson K.M., Wilson P.W., Odell P.M., Kannel W.B. An updated coronary risk profile: a statement for health professionals. Circulation 1991; 83: 356-362.
8. Attman P.Q., Alupovic P. Lipid abnormalities in chronic renal insufficiency. Kidney Int. 1991; 39; (suppl. 31): 16-23.
9. Attman P.Q., Samuelsson O., Alupovic P. Lipoprotein metabolism in renal failure. Am J Kidney Dis 1993; 21: 573-592.
10. Besker B.N., Himmelfarb J., Henrich W.L., Hakim R.M. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997; 8: 475-486.
11. Buckalew V.M.Jr., Berg R.L., Wang S. et al. Prevalents of hypertension in 1,795 subjects with chronic renal disease: The modification of Diet in renal desease study baseline cohort. Am J Kiney Dis 1996; 28: 811-821.
12. Beto J.A., Bansal V.K. Interventions for other risk factors: tobacco use, physical inactivity, menopause, and homocysteine. Am J Kidney Dis 1998; 32 (suppl 3); 172-184.
13. Bikkina M., Levy D., Evans J.C. et al. Left ventricular mass and risk of stroke in a elderly cohort: the Framingham Heart Study. JAMA 1994; 272: 33-36.
14. Brunner F.P., Brover M., Brynger H. et al. Demography of dialysis and transplantation in children in European Dialysis and Transplantant Assosiation Registry. Nephrol Dial Transplant 1988; 3: 235-243.
15. Canadian Organ Replacement Register: 1993 Annual Report. Don Mills, Ontario, Canada, Canadian Institute for Health Information, 1995; 113.
16. Charra B., Calemard M., Laurent G. Importence of treatment time and blood pressure control in achieving long-term survival on dialysis. Am J Nephrol 1996; 16: 35-44.
17. Charra B., Bergstrom J., Scribner B.H. Blood pressure control in dialysis patients: impotence of the lag phenomenen. Am J Kidney Dis 1998; 32: 720-724.
18. Cockcroft D., Gault M.H. Prediction of creatinine clearence from serum creatinine. Nephron 1976; 16: 31-41.
19. Collins A.J., Hao W., Xia H. et al. Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis 1999; 34: 1065-1074.
20. Conlon P.J., Krucolf M.W., Minda S. et al. Incidence and long-term significance of transient S segment deviation in hemodialysis patients. Clin Nephrol 1998; 49: 236-239.
21. Conte F., Limido A., Malberti F. et al. Registro Lomdardo Dialisi e Trapianto. Aggiornamento al. 31/12/1996. Annual Report Regione Lombardia-Direzione Generale Santa, Milano: 1998; 21.12.
22. Cordonrier D., Bayle F., Benhamon P.Y. et al. Future trends of management of renal failure in diabetics. Kidney Int. 1993; 43 (suppl 41): 8-13.
23. Culleton B.F., Larson M.G., Wilson P.W.F. et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999; 56: 2214-2219.
24. Devereux R.B., Alonso D.R., Lutas E.M., Gotlieb G.J. et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Kidney Dis. 1991; 18, Suppl 2: 1-127.
25. Disney A.P. Demografy and survival of patients receiving treatment for chronic renal failure in Australia and New Zealand: Report of dialysis and renal transplantaition treatment from the Australia and New Zealand dialysis and transplant registry. Am J Kidney Dis 1995; 25: 165-175.
26. Dorhout Mees E.J. Hypertention in hemodialysis patients: who cares? Nephrol Dial Transplant 1999; 14: 28-30.
27. Drew P.J.T., Cunnincham J., Evans S.J.W. et al. The effect of cigarette smoking and previous hypertention on the survial of patients treated by continuous ambulatory peritoneal dialysis. Perit Dial Bull 1985; 5: 27-30.
28. Ducimetiere P., Richard J.L. Dietery lipids and coronary disease: in there a French paradox? Nutr Metab Cardiovasc Dis 1992; 2: 195-201.
29. Flather M.D., Yusuf S., Kober L. et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000; 355: 1575-1581.
30. Foley R.N., Parfrey P.S., Harnett J.D. et al. Clinical and echocardiographic disease in end-stage renal disease: prevalens, associations and prognosis. Kidney Int. 1995; 47: 186-192.
31. Foley R.N., Parfrey P.S., Harnett J.D. et al. The prognostic importence of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995; 5: 2024-2031.
32. Foley R.N., Parfrey H.S., Harnett J.D. et al. Impact of hypertension on cardiomyopathy, morbididy and mortality in end stage renal disease. Kidney Int. 1996; 49: 1379-1385.
33. Foley R.N., Parfrey P.S., Harnett J.D. et al. The impact of anemia on cardiomyopathy, morbidity and mortality in end stage renal disease. Am J Kidney Dis.1996; 28: 53-61.
34. Foley R.N., Parfrey P.S., Harnett J.D. et al. Hypoalbuminemia, cardiac morbidity and mortality in end stage renal disease. J Am Soc Nephrol 1996; 7: 728-736.
35. Foley R.N., Parfrey H.S., Harnett J.D. et al. Impact of hypertension on cardiomyopathy, morbididy and mortality in end stage renal disease. Kidney Int. 1996; 49: 1379-1385.
36. Foley R.N., Parfrey P.S., Morgan J. et al. A randomized controlled trial of complete vs partial correction of anemia in hemodialysis patients with asymptomatic concentric LV hypertrophy or LV dilatation [Abstract]. J Am Soc Nephrol 1998; 9: 208A.
37. Foley R.N., Parfrey P.S., Kent G.M. et al. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int. 1998; 54: 1720-1725.
38. Foley R.N., Parfrey P.S., Sarnak M. Epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 199832[Suppl 3]: 12-19, 1998.
39. Friberg P., Nordlander M. Infuence of left ventricular and coronary hypertrophy on cardiac performance. J Hypertens 8; 879-884, 1990.
40. Gentil M., Carriazo A., Pavon M.I. et al. Comparison of survial in continuous ambulatory peritoneal dialysis and hospital hemodialys. A multicentric study. Nephrol Dial Transplant 6: 444-451, 1991.
41. Ghali J.K., Liao Y., Simmons B. et al. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 117: 831-836, 1992.
42. Greaves S.C., Gamble G.D., Collins J.E. et al. Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure. Am J Kidney Dis 24(5): 768-776, 1994.
43. Gross M.L., Amman K., Munter K. et al. Role of the endothelin system in uremic cardiomyopathy. J Amer Soc Nephrol 1997; 8: 616A-617A (Abstract).
44. Heart Outcomes Prevention Evaluation (HOPE) study investigators. Effects of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New Engl J med 342: 145-153, 2000.
45. Held P.J., Levin N.W., Pauly M.V., Diamond L.H. Mortality and duration of hemodialysis treatment. JAMA 265:871-875,1991.
46. Heyka R.J. What are the unique aspects of antihypertensive therapy in dialysis patients? Semin Dial 7: 172-173, 1994.
47. Innes A., Charra B., Burden R.P. et al. The effect of long, slow haemodialysis on patient survival. Nephrol Dial Transplant 14: 919-922, 1999.
48. Jager K.L., Merkus M.P., Dekker F.W. et al. Mortality and technique failure in patients starting chronic peritoneal dialysis: results of the Netherlands Cooperative Study on the adequancy of dialysis. NECOSAD Study Group. Kidney Int 55: 1476-1485, 1999.
49. Kassiske B.L. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 32 (suppl 3): 142-156, 1998.
50. Kassiske B.L., Ma J.K., Roberto S.N. Effects of antihypertensive therapy on serum lipids. Ann intern Med 122, 2: 133-141, 1995.
51. Katzarski K.S., Charra B., Luik A.J. et al. Fluid State and blood pressure control in patients treated with long and short haemodialysis. Nephrol Dial Transplant 14: 369-375, 1999.
52. Klahr S., Levey A.C., Beck G.I. et al. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. Modification of diet in renal disease study group. New Engl J Med 330: 877-884,1994.
53. Koren M.J., Devereux R.B., Cassale P.N. et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertention. Ann Intern Med 114: 345-352, 1991.
54. Kronenberg F., Neyer U., Shotta K. et al. The low molecular weight apo(a)phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 10: 1027-1036, 1999.
55. Lameire N., Bernaert P., Lambert M.C., Vijt D. Cardiovascular risk factors and their management in patients on continuous ambulatory peritoneal dialysis. Kidney Int 46(Suppl 48):31-38,1994.
56. Lanfer E., Jennings G.L., Korner P.I., Dewar E. Prevalence of cardiac structural and functional abnormalities in untreated primary hypertension. Hypertension 13; 151-162, 1989.
57. Lang T., Amouyel P., Arveiler D., Ferrieres J. Why mortality from heart disease in low in France (letter). Br Med J 320: 249-250, 2000.
58. Levey A.S., Beto J.A., Coronado B.E. et al. Controling the epidemic of cardiovascular disease in chronic renal disease. National Kidney Foundation Task Force on cardiovascular disease. Am J Kidney Dis 32: 853-906, 1998.
59. Levin A., Singer J., Thompson C.R., Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 27: 347-354,1996.
60. Levin A., Thompson C.R., Ethier J. et al. Left ventricular mass increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999, 1: 125-134.
61. Levy D., Garrison R., Savage D.D. et al. Prognostic implications of echocardiographically determined left venrticular mass in tre Framingham Heart Study. New Engl J Med 322: 1561-1566, 1990.
62. Locatelli F., Conte F., Marcelli D. The impact of haematocrit levels and erytropoietin treatment on overall and cardiovascular mortality and morbidity - the experience of the Lombardy dialysis registry. Nephrol Dial Transplant 13: 1642-1644, 1998.
63. London G., Parfrey P.S. Cardiac disease in chronic uremia. Pathogenesis. Adv Renal Replace Ther 4: 194-211, 1997.
64. Lowrie E.G., Lew N.L. Death risk in hemodialysis patients: the predictive value of commonly measured variables and evaluation of death rate differences between facilities. Am J Kidney Dis 15: 458-482, 1990.
65. Lubbecke F., Matthias F.R., Richer U. et al. Coronary risk factors in chronic hemodialysis patients. Med Klin 91(11):687-693,1996.
66. Luke R.G. Chronic renal failure: a vasculopathic state. N Engl J Med 339: 841-843,1998.
67. Ma K.W., Greene E.L., Raij L. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis 26: 505-513, 1992.
68. Mailloux L.U., Napolitano B., Bellucci A.G. et al. The impact of co-morbid risk factors at the start of dialysis upon the survival of ESRD patients. ASAIO J 42: 164-169, 1996.
69. Mailloux L.U., Haley W.E. Hypertention in the ESRD patient: pathophysiology, therapy, outcomes, and future directions. Amer J Kidney Dis 32: 705-719, 1998.
70. Maiorca R., Vonesh E.F., Cavalli P.L. et al. A multicenter selection-adjusted comparison of patient and technique survivals on CAPD and hemodialysis. Perit Dial Int 11: 118-127, 1991.
71. Malberti F., Conte F., Limido A. et al. Ten years experience of renal replacement treatment in the elderly. Geriatr Nephrol Urol 7: 1-10, 1997.
72. Massy Z.A. Importance of homocysteine, lipoprotein (a), and non-classical cardiovascular risk factors (fibrinogen, and advanced glycation end products) for atherogenesis in uremic patients. Nephrol Dial Transplant 15 (suppl 5): 81-91, 2000-12-13.
73. MERIT-HT Study Group. Effect of metoprolol CR/X in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HT). Lancet 353: 2001-2007, 1999.
74. Mignon F., Michel C., Mentre F., Viron B. Worldwide demographies and future trends of the management of renal failure in the elderly. Kidney Int 43 (suppl 41): 18-26, 1993.
75. Morishita R., Gibbons G., Ellison K. et al. Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. J Clinical Investig 94: 978-984, 1994.
76. National Kidney Foundation Task Force on cardiovascular disease: controlling the epidemic of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32(suppl 3): 1-199,1998.
77. Paolo B.D., Liberato L.D., Fiederling B. et al. Incidence and pathophysiology of hypertension in continuous ambulatory peritoneal dialysis. Perit Dial Int 13 (suppl 2): 396-398, 1993.
78. Parfrey P.S. (editor): Cardiac disease in chronic uremia: Uremia-related risk factors. Semin Dial 12: 1-132,1999.
79. Parfrey P.S. Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant 15 (suppl 5): 58-68, 2000.
80. Perino G.C., Ragni R., Salomone M. Analysis of cause of death in the first and last periods of the Peidmontese dialysis and transplantation registry. Minerva Urol Nephrol 50: 71-74, 1998.
81. Port F.K., Hulbert-Shearon T.E., Wolfe R.A. et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 33: 507-517, 1999.
82. Preston R.A., Singer I., Epstein M. Renal parenchymal hypertension current concepts of pathogenesis and management. Arch Intern Med 156: 602-611, 1996.
83. Rahman M., Dixit A., Donley V. et al. Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients. Am J Kidney Dis 33: 498-506, 1999.
84. Raine A.E.G., Margreiter R., Brunner F.P. et al. Report on management of renal failure in Europe, XX11,1991. Nephrol Dial Transplant 7 (suppl 2): 7-35,1992.
85. Rostand S.G., Rutsky E.A. Ischemic heart disease in chronic renal failure: demography, epidemiology and pathogenesis.// Cardiac dysfunction in chronic uremia. Eds. PS Parfrey, JD Parfrey, JD Harnett. Norwell 4: 54-66, 1992.
86. Rubin H.R., Jenckea M., Fink N.E. et al. For the CHOICE study. Patients view of dialysis care: development of a taxonomy and rating of importence of different aspects of care. Am J Kidney Dis 30: 793-801, 1997.
87. Sabbah H.N. Tre cellular and physiologic effects of beta blockers in heart failure. Clin Cardiol 22 (suppl 5): 16-20, 1999.
88. Salem M.M., Bower J.D. Hypertensionin the hemodialysis population. Am J Kidney Dis 29: 811-812, 1997.
89. Serkes K.D., Blagg C.R., Nolph K.D. et al. Comparison of patient and technique survival in continuous peritoneal dialysis and hemodialysis: A multicenter study. Perit Dial Int 10: 15-19, 1990.
90. Silberberg J.S., Barre P.E., Prichard S.S. et al. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36: 286-290,1989.
91. The Sixth Report of the Joint National Committee on Prevention, Detection, Evalution, fnd Treatment of High Blood Pressure. Arch. Intern. Med. 1997; 157: 2413-2446.
92. Toto R.D., Mitchell H.C., Smith R.D. et al. «Strict» blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Jnt 48: 851-859, 1995.
93. Tsakiris D., Jones E.H. Deaths within 90 days from starting renal replacement therapy in the renal replacement therapy in the ERA-EDTA Registry between 1990 and 1992. Nephrol Dial Transplant 14: 2343-2350, 1999.
94. Tschope W., Koch M., Thomas B., Ritz E. and German Study Group Diabetes and Uremia: Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis: Results of a prospective study. Nephron 64: 354-358,1993.
95. U.S. Renal Data System: USRDS 1998 Annual Data Report, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, April 1998.
96. U.S. Renal Data System, 1999 Annual Data Report. Am J Kidney Dis 34 (suppl 1), 1999.
97. Valderabano F., Berthous F.C., Jones E.H., Mehs O. Report on management of renal failure in Europe, XXY, 1994. End stage renal desease and dialysis report. Nephrol Dial Transplant 11(suppl 1): 2-21, 1996.
98. Valsania P., Sarich S.W., Kowalchuk G.J. Severity of coronary artery disease in young patients with insulin-dependent diabetes mellitus. Am Heart J 122: 695-700,1991.
99. Webb A.T., Reaveley D.A., O’Donnel M. et al. Lipids and lipoprotein as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant 5: 354-357, 1994.
100. Wheeler D.C. Abnormalities of lipoprotein metabolism in CAPD patients. Kidney Jnt 50 (suppl 56): 41-46, 1996.
101. World Health Statistics Annu,al 196, 1998.

Другие статьи по теме

• К вопросу о значении специфических антигензависимых и неспецифических факторов в патогенезе хронической трансплантационной нефропатии
• Паратиреоидный гормон - универсальный уремический токсин (Обзор литературы)
• Нутриционный статус больных на перитонеальном диализе
• Роль паратиреоидного гормона и витамина D в развитии кардиоваскулярных нарушений при хронической почечной недостаточности (Обзор литературы)